A detailed history of Rhenman & Partners Asset Management Ab transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 47,750 shares of VRTX stock, worth $22.4 Million. This represents 1.85% of its overall portfolio holdings.

Number of Shares
47,750
Previous 54,000 11.57%
Holding current value
$22.4 Million
Previous $25.3 Million 12.26%
% of portfolio
1.85%
Previous 2.5%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$460.0 - $505.78 $2.88 Million - $3.16 Million
-6,250 Reduced 11.57%
47,750 $22.2 Million
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $982,025 - $1.21 Million
-2,500 Reduced 4.42%
54,000 $25.3 Million
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $15.7 Million - $17.2 Million
-38,500 Reduced 40.53%
56,500 $23.6 Million
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $6.35 Million - $7.6 Million
18,500 Added 24.18%
95,000 $38.7 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $14 Million - $15 Million
41,500 Added 118.57%
76,500 $26.6 Million
Q3 2023

Nov 09, 2023

SELL
$338.18 - $362.46 $9.64 Million - $10.3 Million
-28,500 Reduced 44.88%
35,000 $12.2 Million
Q2 2023

Aug 11, 2023

SELL
$314.42 - $351.91 $6.29 Million - $7.04 Million
-20,000 Reduced 23.95%
63,500 $22.3 Million
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $991,305 - $1.13 Million
3,500 Added 4.38%
83,500 $26.3 Million
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $4.57 Million - $5.14 Million
-16,000 Reduced 16.67%
80,000 $23.1 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $273,830 - $305,530
1,000 Added 1.05%
96,000 $30 Million
Q2 2022

Aug 12, 2022

BUY
$234.96 - $292.55 $1.29 Million - $1.61 Million
5,500 Added 6.15%
95,000 $26.8 Million
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $16.7 Million - $19.7 Million
-75,500 Reduced 45.76%
89,500 $23.4 Million
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $9.23 Million - $10.3 Million
-50,897 Reduced 23.57%
165,000 $29.9 Million
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $8.9 Million - $10.5 Million
47,476 Added 28.19%
215,897 $43.5 Million
Q1 2021

May 14, 2021

BUY
$207.02 - $241.31 $11.1 Million - $12.9 Million
53,421 Added 46.45%
168,421 $36.2 Million
Q4 2020

Jan 19, 2021

BUY
$207.01 - $276.09 $1.04 Million - $1.38 Million
5,000 Added 4.55%
115,000 $27.2 Million
Q3 2020

Oct 13, 2020

SELL
$255.65 - $303.1 $7.03 Million - $8.34 Million
-27,500 Reduced 20.0%
110,000 $29.9 Million
Q2 2020

Jul 16, 2020

BUY
$225.48 - $295.8 $5.07 Million - $6.66 Million
22,500 Added 19.57%
137,500 $39.9 Million
Q1 2020

Apr 16, 2020

SELL
$199.77 - $247.81 $8.99 Million - $11.2 Million
-45,000 Reduced 28.13%
115,000 $27.4 Million
Q4 2019

Jan 17, 2020

SELL
$166.71 - $223.91 $4.33 Million - $5.82 Million
-26,000 Reduced 13.98%
160,000 $35 Million
Q3 2019

Oct 16, 2019

BUY
$166.23 - $187.09 $127,664 - $143,685
768 Added 0.41%
186,000 $31.5 Million
Q2 2019

Jul 22, 2019

BUY
$164.61 - $190.37 $6.72 Million - $7.77 Million
40,832 Added 28.28%
185,232 $34 Million
Q1 2019

Apr 11, 2019

BUY
$163.73 - $194.7 $1.96 Million - $2.33 Million
11,975 Added 9.04%
144,400 $26.6 Million
Q4 2018

Feb 05, 2019

SELL
$151.91 - $192.21 $1.53 Million - $1.93 Million
-10,040 Reduced 7.05%
132,425 $21.9 Million
Q3 2018

Oct 03, 2018

SELL
$167.73 - $192.74 $2.1 Million - $2.42 Million
-12,535 Reduced 8.09%
142,465 $27.5 Million
Q2 2018

Jul 20, 2018

BUY
$145.72 - $169.96 $728,600 - $849,800
5,000 Added 3.33%
155,000 $26.3 Million
Q1 2018

Apr 11, 2018

SELL
$151.6 - $177.13 $334,126 - $390,394
-2,204 Reduced 1.45%
150,000 $24.4 Million
Q4 2017

Jan 19, 2018

SELL
$137.28 - $155.55 $3.82 Million - $4.32 Million
-27,796 Reduced 15.44%
152,204 $22.8 Million
Q3 2017

Oct 13, 2017

BUY
$148.13 - $162.24 $26.7 Million - $29.2 Million
180,000
180,000 $27.4 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.